Lewy身体痴呆治疗市场份额，规模，趋势，行业分析报告，用药物类型（Modafinil，Cholinesterase抑制剂，苯二氮卓，抗精神病药，抗抑郁药和碳酸-Levodopa）;通过指示[帕金森病和痴呆症，用lewy尸体（dlb）];通过分销渠道;由地区分部预测，2020 - 2027年

报告摘要

The global Lewy body dementia treatment market was valued at USD 3,597.93 million in 2019 and is expected to reach USD 5,311.41 million by 2027, growing at a CAGR of 5.08% during 2020-2027. The market factors attributed to the market growth are a rise in the geriatric population across the world, exposure to carcinogenic pollutants causing mutation in the onset of Lewy body deposition i.e.; intracellular alpha-synuclein, on-going industry-academia collaboration, and the people with a genetic history of dementia.

Lewy body dementia is most common, after Alzheimer’s disease. Lewy body dementia usually happens to people over the age of 50 or above. Lewy body dementia is a growing disease, which starts with mild symptoms and gets worse over time. The disease is prolonged for 5 to 8 years till death from the time of diagnosis, but the duration of the disease can range from 2 to 20 years. The rising conditions of brain-related diseases among the population are anticipated to drive demand.

了解有关此报告的更多信息：request for sample pages

Industry Dynamics

Growth Drivers
由于临床试验的临床试验和清关的审批和清关，预计石油体内痴呆症治疗市场预计会有显着的增长和临床试验和毒品的研究。脑与脑相关疾病的普遍性升高了需要有效治疗的需求，因此导致市场增长。例如，在2020年8月，Eli Lilly和公司已经完成了Ly3154207的临床研究，患有石油体痴呆（LBD）或特发性帕金森病（PD）的患者。与痴呆症有关的提高意识，以防止对中枢神经系统和机身运动损坏的风险导致了对石油患者痴呆治疗市场的需求不断增长。预计将增加与石油体内痴呆症的医疗药物的批准将增加对全球市场的需求。

A rise in the initiatives taken by the market players such as developing new methods, drugs, and the issue of patents to manufacture new methods is anticipated to foster the growth of the global market. For instance, in February 2020, a clinical-stage drug platform company, Annovis Bio Inc. issued a patent (US 10,383,851) for developing a method to address Lewy Body Dementia and Parkinson’s disease.

Lewy身体痴呆治疗市场Report Scope

The market is primarily segmented on the basis of drug type, indication, distribution channel, and geographic region.

通过药物类型	通过指示	通过分销渠道	按地区
Modafinil Cholinesterase Inhibitors Benzodiazepine Antipsychotic Drugs 抗抑郁药 Carbidopa-Levodopa	Parkinson’s Disease Dementia with Lewy Bodies (DLB)	Drug Stores Hospitals Pharmacies Online Pharmacies 零售药房	北美（美国，加拿大） 欧洲（法国，德国，英国，意大利，西班牙，荷兰，奥地利） Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) 拉丁美洲（巴西，墨西哥，阿根廷） 中东和非洲（沙特阿拉伯，阿联酋，以色列，南非）

了解有关此报告的更多信息：request for sample pages

药物类型的洞察力

在药物类型的基础上，全球市场分为Modafinil，Cholinesterase抑制剂，苯二氮卓，抗精神病药，抗抑郁药和Carbidopa-Levodopa。在专注于药物类型的情况下，胆碱酯酶抑制剂部分持有全球市场的最大占有率。抗精神病药分部已经占全球市场的第二大份额。全球市场的主导地位归因于在治疗患者期间的最小副作用。

介绍介绍

的基础上,全球市场是bifurcated into Parkinson's disease and dementia with Lewy bodies. The segment DLB (Dementia with Lewy Body) is the second most prevailing disorder after Alzheimer’s dementia in the population. The segment of Parkinson's disease has been proved to turnout the rapid growing disease with the central nervous system disorder and other symptoms such as stiffness, loss of balance, and slow movement. The indication segment of the global market is rapidly growing due to the rising cases of dementia disorder.

Insight by Distribution Channel

On the basis of the distribution channel, the market is segmented into drug stores, hospital pharmacies, online pharmacies, and retail pharmacies. The hospital segment is expected to hold the major revenue share of the global market due to the high usage of the drugs, medications, etc. at hospitals, associated with dementia treatment. The online pharmacies segment accounted to witness the lucrative growth followed by the retail pharmacies and drug stores due to the rising incidence and growing awareness of an individual for dementia treatment. It is also expected to drive the demand for channel segments and a subsequent surge in the global market.

Geographic Overview

由于该地区痴呆症患病的高血目，北美有望见证巨大增长。该地区的不断增长的老年人口是影响全球市场需求的主要因素之一，这是由于患有石油体痴呆症受影响的风险。For instance, in February 2019, BioArctic AB, a Swedish research-based biopharma company, declared that AbbVie has received approval from the U.S. Food and Drug Administration of IND application for ABBV-0805 to address the patients suffering from Lewy body dementia and Parkinson’s disease. The key players in the market have adopted acquisition as a strategy to expand their regional presence. For instance, in January 2019, Takeda Pharmaceutical Company Limited acquired Shire plc. This acquisition has shifted Takeda Pharmaceutical to become a leading global player in the biopharmaceutical industry in Japan and influenced the demand in Asia Pacific.

竞争洞察力

市场的主要球员专注于通过采用区域扩张等策略，进入伙伴关系和合资企业和兼并和收购来增加市场份额。例如，在2020年8月2020年代，华盛州达海甘制药具有限公司与Aikomi，Ltd.一起制造和开发医疗器械，以提供有效和安全的治疗，并防止心理和安全行为症状。

Some of the major players operating in the market include Mallinckrodt Pharmaceuticals, BioArctic AB, Bausch Health Companies Inc., Sumitomo Dainippon Pharma Co., Ltd., Janssen Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Allergan Plc., Noven Pharmaceuticals, Inc., Takeda Pharmaceutical Company Ltd., Eli Lilly and Company, Eisai Co., Ltd., Novartis AG, GlaxoSmithKline, Pfizer Inc., Teva Pharmaceuticals, Bayer AG, Sanofi AG, and Mylan NV.